Akshay Khatri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Akshay Khatri has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Yoichiro Natori
Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine , Miami, Florida
5 shared publications - Giselle Guerra
University of Miami Miller School of Medicine, Miami Transplant Institute, Miami, Florida
3 shared publications - Jacques Simkins
Jackson Memorial Hospital Miami Florida USA
3 shared publications - Jose Fernando Camargo
Division of Infectious Diseases Miami Florida 33136 University of Miami Department of Medicine
3 shared publications - Julia Bini Viotti
Division of Infectious Diseases Miami Transplant Institute University of Miami Miami Florida USA
3 shared publications Michele I. Morris
Division of Infectious Disease, Department of Medicine University of Miami Miller School of Medicine Miami Florida USA
3 shared publications
Latest Publications
- 4 April 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70207
Screening and Reactivation of Chagas Disease Among Solid Organ Transplant Candidates and Recipients: A 10‐Year Single Center Experience in Florida
Background: Chagas disease (CD), a neglected tropical disease usually associated with Latin America, is increasingly recognized as an emerging infection in the United States. Screening for CD is recommended for solid organ transplant (SOT) candidates with epidemiologic risk factors; however, data on prevalence and post‐transplant reactivation in the United States remain limited. Methods: We conducted a retrospective cohort study of SOT candidates and recipients screened for T. cruzi at a large transplant center in Miami, Florida. Demographics, clinical characteristics, and 2‐year outcomes of recipients with CD were analyzed. Results: Between August 1, 2013, and August 1, 2023, 6021 SOTs were performed. 1898 candidates (31%) were screened, and 21 (1.1%) tested positive for T. cruzi , of whom 10 were SOT recipients. All seropositive recipients were born in historically endemic areas. Median post‐transplant surveillance was 13.5 (range 1–25) months. Seven patients developed Chagas disease reactivation (CDR) diagnosed by serum PCR; all were asymptomatic. Median time from transplantation to reactivation was 48 days (range 22–426). Treatment with benznidazole for 60 days cleared the parasitemia in all patients. At 2 years, 80% (8/10) had graft survival, one patient died unrelated to CDR. Conclusion: We report a high incidence of CDR among SOT recipients at a US transplant center serving a predominantly immigrant population, with favorable 2‐year outcomes. Most reactivation events occurred early post‐transplant, although a later recurrence was also observed. Intensive monitoring for CDR proved effective in detecting reactivation prior to the onset of symptoms.
- 4 April 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70207
Screening and Reactivation of Chagas Disease Among Solid Organ Transplant Candidates and Recipients: A 10‐Year Single Center Experience in Florida
Background: Chagas disease (CD), a neglected tropical disease usually associated with Latin America, is increasingly recognized as an emerging infection in the United States. Screening for CD is recommended for solid organ transplant (SOT) candidates with epidemiologic risk factors; however, data on prevalence and post‐transplant reactivation in the United States remain limited. Methods: We conducted a retrospective cohort study of SOT candidates and recipients screened for T. cruzi at a large transplant center in Miami, Florida. Demographics, clinical characteristics, and 2‐year outcomes of recipients with CD were analyzed. Results: Between August 1, 2013, and August 1, 2023, 6021 SOTs were performed. 1898 candidates (31%) were screened, and 21 (1.1%) tested positive for T. cruzi , of whom 10 were SOT recipients. All seropositive recipients were born in historically endemic areas. Median post‐transplant surveillance was 13.5 (range 1–25) months. Seven patients developed Chagas disease reactivation (CDR) diagnosed by serum PCR; all were asymptomatic. Median time from transplantation to reactivation was 48 days (range 22–426). Treatment with benznidazole for 60 days cleared the parasitemia in all patients. At 2 years, 80% (8/10) had graft survival, one patient died unrelated to CDR. Conclusion: We report a high incidence of CDR among SOT recipients at a US transplant center serving a predominantly immigrant population, with favorable 2‐year outcomes. Most reactivation events occurred early post‐transplant, although a later recurrence was also observed. Intensive monitoring for CDR proved effective in detecting reactivation prior to the onset of symptoms.
- Open Access
- 4 October 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (S1) , e14162
Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients
Background: Isavuconazole (ISA) is a newer antifungal used in patients with history of hematologic malignancies and hematopoietic transplant and cellular therapies (HM/TCT). Although it has a more favorable side‐effect profile, breakthrough invasive fungal infections (bIFIs) while on ISA have been reported.Methods: In this single‐center retrospective study evaluating HM/TCT patients who received prophylactic ISA for ≥7 days, we evaluated the incidence and potential risk factors for bIFIs.Results: We evaluated 106 patients who received prophylactic ISA. The patients were predominantly male (60.4%) with median age of 65 (range: 21–91) years. Acute myeloid leukemia (48/106, 45.3%) was the most common HM, with majority having relapsed and/or refractory disease (43/106, 40.6%) or receiving ongoing therapy (38/106, 35.8%).Nineteen patients (17.9%) developed bIFIs–nine proven [Fusarium (3), Candida (2), Mucorales plus Aspergillus (2), Mucorales (1), Colletotrichum (1)], four probable invasive pulmonary Aspergillus, and six possible infections. Twelve patients were neutropenic for a median of 28 (8–253) days prior to bIFI diagnosis. ISA levels checked within 7 days of bIFI diagnosis (median: 3.65 μg/mL) were comparable to industry‐sponsored clinical trials.All‐cause mortality among the bIFI cases was 47.4% (9/19).We also noted clinically significant cytomegalovirus co‐infection in 5.3% (1/19). On univariate analysis, there were no significant differences in baseline comorbidities and potential risk factors between the two groups.Conclusion: ISA prophylaxis was associated with a significant cumulative incidence of bIFIs. Despite the appealing side‐effect and drug‐interaction profile of ISA, clinicians must be vigilant about the potential risk for bIFIs. image
- 4 October 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (S1) , e14162
Open AccessBreakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients
Background: Isavuconazole (ISA) is a newer antifungal used in patients with history of hematologic malignancies and hematopoietic transplant and cellular therapies (HM/TCT). Although it has a more favorable side‐effect profile, breakthrough invasive fungal infections (bIFIs) while on ISA have been reported.Methods: In this single‐center retrospective study evaluating HM/TCT patients who received prophylactic ISA for ≥7 days, we evaluated the incidence and potential risk factors for bIFIs.Results: We evaluated 106 patients who received prophylactic ISA. The patients were predominantly male (60.4%) with median age of 65 (range: 21–91) years. Acute myeloid leukemia (48/106, 45.3%) was the most common HM, with majority having relapsed and/or refractory disease (43/106, 40.6%) or receiving ongoing therapy (38/106, 35.8%).Nineteen patients (17.9%) developed bIFIs–nine proven [Fusarium (3), Candida (2), Mucorales plus Aspergillus (2), Mucorales (1), Colletotrichum (1)], four probable invasive pulmonary Aspergillus, and six possible infections. Twelve patients were neutropenic for a median of 28 (8–253) days prior to bIFI diagnosis. ISA levels checked within 7 days of bIFI diagnosis (median: 3.65 μg/mL) were comparable to industry‐sponsored clinical trials.All‐cause mortality among the bIFI cases was 47.4% (9/19).We also noted clinically significant cytomegalovirus co‐infection in 5.3% (1/19). On univariate analysis, there were no significant differences in baseline comorbidities and potential risk factors between the two groups.Conclusion: ISA prophylaxis was associated with a significant cumulative incidence of bIFIs. Despite the appealing side‐effect and drug‐interaction profile of ISA, clinicians must be vigilant about the potential risk for bIFIs. image
- 27 January 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (1) , e14006
Early administration of SARS‐CoV‐2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID‐19
Background: Data on severe acute respiratory distress syndrome coronavirus 2 monoclonal antibody (SARS‐CoV‐2‐specific mAb) use in hematologic malignancy and hematopoietic cell transplantation (HM/HCT) patients are limited. Here, we describe our experience with the use of casirivimab–imdevimab or bamlanivimab for the treatment of coronavirus disease 2019 (COVID‐19) in HM/HCT patients.Methods: This was a retrospective chart review at the University of Miami Hospital and Sylvester Comprehensive Cancer Center for HM/HCT patients with COVID‐19 who received casirivimab–imdevimab or bamlanivimab from November 21, 2020, to September 30, 2021. Outcomes measured were mortality, hospital admission, and infusion reaction to SARS‐CoV‐2‐specific mAbs.Results: We identified 59 HM/HCT patients with mild to moderate COVID‐19 who received casirivimab–imdevimab or bamlanivimab. Median age was 57 years (interquartile range [IQR]: 45–65). Among the 59 patients, 25 (42%) received cellular therapy: 14 (24%) had undergone allogeneic HCT, nine (15%) autologous HCT, and two (3%) received chimeric antigen receptor T‐cell therapy. The median time from COVID‐19 symptom onset to SARS‐CoV‐2‐specific mAb administration was 4 (IQR: 3–6) days. Forty‐six (78%) patients received SARS‐CoV‐2‐specific mAbs as outpatients and 13 (22%) patients received SARS‐CoV‐2‐specific mAbs during hospitalization. Among patients who received SARS‐CoV‐2‐specific mAbs as outpatients, only four (9%) visited the emergency department at days 10, 11, 15, and 35 after SARS‐CoV‐2‐specific mAb administration. None of these four patients required hospital admission. Among the hospitalized patients, five (38%) were admitted to the hospital with neutropenic fever, four (31%) were already hospitalized for transplantation and cellular therapy, three (23%) were admitted for monitoring of COVID‐19 symptoms, and one (8%) was admitted with acute kidney injury. Three hospitalized patients (23%) died at 14, 35, and 59 days after SARS‐CoV‐2‐specific mAb administration; two of these three deaths were attributed to COVID‐19 infection. One patient developed an immediate infusion reaction to bamlanivimab, and no infusion reactions were reported to casirivimab–imdevimab use.Conclusion: During the alpha and delta variant surges, early administration of bamlanivimab or casirivimab–imdevimab prevented hospitalization and death when given in the outpatient setting. Among patients who received mAbs at or after hospital admission, the risk of COVID‐19 disease progression and death remains significant. Larger studies of the use of mAb therapy to treat COVID‐19 in this population are needed. image
- 27 January 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (1) , e14006
Early administration of SARS‐CoV‐2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID‐19
Background: Data on severe acute respiratory distress syndrome coronavirus 2 monoclonal antibody (SARS‐CoV‐2‐specific mAb) use in hematologic malignancy and hematopoietic cell transplantation (HM/HCT) patients are limited. Here, we describe our experience with the use of casirivimab–imdevimab or bamlanivimab for the treatment of coronavirus disease 2019 (COVID‐19) in HM/HCT patients.Methods: This was a retrospective chart review at the University of Miami Hospital and Sylvester Comprehensive Cancer Center for HM/HCT patients with COVID‐19 who received casirivimab–imdevimab or bamlanivimab from November 21, 2020, to September 30, 2021. Outcomes measured were mortality, hospital admission, and infusion reaction to SARS‐CoV‐2‐specific mAbs.Results: We identified 59 HM/HCT patients with mild to moderate COVID‐19 who received casirivimab–imdevimab or bamlanivimab. Median age was 57 years (interquartile range [IQR]: 45–65). Among the 59 patients, 25 (42%) received cellular therapy: 14 (24%) had undergone allogeneic HCT, nine (15%) autologous HCT, and two (3%) received chimeric antigen receptor T‐cell therapy. The median time from COVID‐19 symptom onset to SARS‐CoV‐2‐specific mAb administration was 4 (IQR: 3–6) days. Forty‐six (78%) patients received SARS‐CoV‐2‐specific mAbs as outpatients and 13 (22%) patients received SARS‐CoV‐2‐specific mAbs during hospitalization. Among patients who received SARS‐CoV‐2‐specific mAbs as outpatients, only four (9%) visited the emergency department at days 10, 11, 15, and 35 after SARS‐CoV‐2‐specific mAb administration. None of these four patients required hospital admission. Among the hospitalized patients, five (38%) were admitted to the hospital with neutropenic fever, four (31%) were already hospitalized for transplantation and cellular therapy, three (23%) were admitted for monitoring of COVID‐19 symptoms, and one (8%) was admitted with acute kidney injury. Three hospitalized patients (23%) died at 14, 35, and 59 days after SARS‐CoV‐2‐specific mAb administration; two of these three deaths were attributed to COVID‐19 infection. One patient developed an immediate infusion reaction to bamlanivimab, and no infusion reactions were reported to casirivimab–imdevimab use.Conclusion: During the alpha and delta variant surges, early administration of bamlanivimab or casirivimab–imdevimab prevented hospitalization and death when given in the outpatient setting. Among patients who received mAbs at or after hospital admission, the risk of COVID‐19 disease progression and death remains significant. Larger studies of the use of mAb therapy to treat COVID‐19 in this population are needed. image
- Open Access
- 13 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9S) , S182-S183
249.1: Outcomes With Omicron Variant of Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) Virus in Solid Organ Transplant Recipients
- 13 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9S) , S182-S183
Open Access249.1: Outcomes With Omicron Variant of Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) Virus in Solid Organ Transplant Recipients
- Open Access
- 12 August 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (6) , e13923
Is the Omicron variant truly less virulent in solid organ transplant recipients?
Solid organ transplant (SOT) recipients are at high risk for severe disease with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Emerging variants of concern have disproportionately affected this population. Data on severity and outcomes with the Omicron variant in SOT recipients are limited. Thus we conducted this single‐center, retrospective cohort study of SOT recipients diagnosed with SARS‐CoV‐2 infection from December 18, 2021 to January 18, 2022, when prevalence of the Omicron variant was more than 80%‐95% in the community. Univariate and multivariate logistic regression analysis was performed to identify risk factors for hospital admission. We identified 166 SOT patients: 112 (67.5%) kidney, 22 (13.3%) liver, 10 (6.0%) lung, seven (4.2%) heart, and 15 (9.0%) combined transplants. SARS‐CoV‐2 vaccine series was completed in 59 (35.5%) recipients. Ninety‐nine (59.6%) and 13 (7.8%) recipients received casirivimab/imdevimab and sotrovimab, respectively. Fifty‐three (32%) recipients required hospital admission, of which 19 (35.8%) required intensive care unit level of care. Median follow‐up was 50 (interquartile range, 25‐59) days, with mortality reported in six (3.6%) patients. Risk factors identified for hospital admission were African American race (p < .001, odds ratio [OR] 4.00, 95% confidence interval [CI] 1.84‐8.70), history of coronary artery disease (p = .031, OR 3.50, 95% CI 1.12‐10.87), and maintenance immunosuppression with corticosteroids (p = .048, OR 2.00, 95% CI 1.01‐4.00). In conclusion, contrary to that in the general population, we found a higher hospital admission rate in SOT recipients with omicron variant infection. Further studies to investigate the efficacy of newer treatments are necessary, even as outcomes continue to improve. image
- 12 August 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (6) , e13923
Open AccessIs the Omicron variant truly less virulent in solid organ transplant recipients?
Solid organ transplant (SOT) recipients are at high risk for severe disease with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Emerging variants of concern have disproportionately affected this population. Data on severity and outcomes with the Omicron variant in SOT recipients are limited. Thus we conducted this single‐center, retrospective cohort study of SOT recipients diagnosed with SARS‐CoV‐2 infection from December 18, 2021 to January 18, 2022, when prevalence of the Omicron variant was more than 80%‐95% in the community. Univariate and multivariate logistic regression analysis was performed to identify risk factors for hospital admission. We identified 166 SOT patients: 112 (67.5%) kidney, 22 (13.3%) liver, 10 (6.0%) lung, seven (4.2%) heart, and 15 (9.0%) combined transplants. SARS‐CoV‐2 vaccine series was completed in 59 (35.5%) recipients. Ninety‐nine (59.6%) and 13 (7.8%) recipients received casirivimab/imdevimab and sotrovimab, respectively. Fifty‐three (32%) recipients required hospital admission, of which 19 (35.8%) required intensive care unit level of care. Median follow‐up was 50 (interquartile range, 25‐59) days, with mortality reported in six (3.6%) patients. Risk factors identified for hospital admission were African American race (p < .001, odds ratio [OR] 4.00, 95% confidence interval [CI] 1.84‐8.70), history of coronary artery disease (p = .031, OR 3.50, 95% CI 1.12‐10.87), and maintenance immunosuppression with corticosteroids (p = .048, OR 2.00, 95% CI 1.01‐4.00). In conclusion, contrary to that in the general population, we found a higher hospital admission rate in SOT recipients with omicron variant infection. Further studies to investigate the efficacy of newer treatments are necessary, even as outcomes continue to improve. image
- Open Access
- 2 February 2022
- Published by Microbiology Society in Access Microbiology
- Vol. 4 (2) , 000308
Unusual presentation of Nocardia abscessus infection in an immunocompetent patient
Introduction. Nocardia infections are being increasingly reported in both immunocompetent and immunocompromised patients. We describe a case of Nocardia abscessus infection with an atypical presentation in an immunocompetent patient. Case Presentation. A previously healthy 47-year-old gentleman presented with hiccups and paroxysmal spasms. Imaging revealed a pulmonary nodule, for which he underwent surgical resection. Pathologic evaluation demonstrated evidence of local inflammation, with growth of Nocardia abscessus on tissue cultures. Conclusion. Nocardia abscessus may have atypical presentations in immunocompetent patients. Further research is needed to understand the factors leading to Nocardia infections in immunocompetent patients.
- 2 February 2022
- Published by Microbiology Society in Access Microbiology
- Vol. 4 (2) , 000308
Open AccessUnusual presentation of Nocardia abscessus infection in an immunocompetent patient
Introduction. Nocardia infections are being increasingly reported in both immunocompetent and immunocompromised patients. We describe a case of Nocardia abscessus infection with an atypical presentation in an immunocompetent patient. Case Presentation. A previously healthy 47-year-old gentleman presented with hiccups and paroxysmal spasms. Imaging revealed a pulmonary nodule, for which he underwent surgical resection. Pathologic evaluation demonstrated evidence of local inflammation, with growth of Nocardia abscessus on tissue cultures. Conclusion. Nocardia abscessus may have atypical presentations in immunocompetent patients. Further research is needed to understand the factors leading to Nocardia infections in immunocompetent patients.
- Open Access
- 12 December 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (5) , 1492-1493
True effect of monoclonal antibody for COVID-19 in kidney transplant recipients
- 12 December 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (5) , 1492-1493
Open AccessTrue effect of monoclonal antibody for COVID-19 in kidney transplant recipients
- 18 September 2021
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (9) , 1710-1711
Addition of Oral Fosfomycin to Antimicrobial Salvage Therapy for Persistent Vancomycin-Resistant Enterococcal Bacteremia
- 18 September 2021
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (9) , 1710-1711
Addition of Oral Fosfomycin to Antimicrobial Salvage Therapy for Persistent Vancomycin-Resistant Enterococcal Bacteremia
- Open Access
- 30 June 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (7) , ofab339
Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
Immunosuppressive therapies proposed for Coronavirus disease 2019 (COVID-19) management may predispose to secondary infections. We evaluated the association of immunosuppressive therapies with bloodstream-infections (BSIs) in hospitalized COVID-19 patients. This was an institutional review board-approved retrospective, multicenter, cohort study of adults hospitalized with COVID-19 over a 5-month period. We obtained clinical, microbiologic and laboratory data from electronic medical records. Propensity-score-matching helped create balanced exposure groups. Demographic characteristics were compared across outcome groups (BSI/no BSI) using two-sample t-test and Chi-Square test for continuous and categorical variables respectively, while immunosuppressive therapy use was compared using McNemar’s test. Conditional logistic regression helped assess the association between immunosuppressive therapies and BSIs. 13,007 patients were originally included, with propensity-score-matching producing a sample of 6,520 patients. 3.74% and 3.97% were diagnosed with clinically significant BSIs in the original and propensity-score-matched populations respectively. COVID-19 patients with BSIs had significantly longer hospitalizations, higher intensive care unit admission and mortality rates compared to those without BSIs. On univariable analysis, combinations of corticosteroids/anakinra [odds-ratio (OR) 2.00, 95% confidence intervals (C.I.) 1.05-3.80, P value.0342] and corticosteroids/tocilizumab [OR 2.13, 95% C.I. 1.16–3.94, P value .0155] were significantly associated with BSIs. On multivariable analysis (adjusting for confounders), combination corticosteroids/tocilizumab were significantly associated with any BSI [OR 1.97, 95% C.I. 1.04–3.73, P value.0386] and with bacterial BSIs [OR 2.13, 95% C.I. 1.12–4.05, p-value 0.0217]. Combination immunosuppressive therapies were significantly associated with BSI occurrence in COVID-19 patients; their use warrants increased BSI surveillance. Further studies are needed to establish their causative role.
- 30 June 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (7) , ofab339
Open AccessHospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
Immunosuppressive therapies proposed for Coronavirus disease 2019 (COVID-19) management may predispose to secondary infections. We evaluated the association of immunosuppressive therapies with bloodstream-infections (BSIs) in hospitalized COVID-19 patients. This was an institutional review board-approved retrospective, multicenter, cohort study of adults hospitalized with COVID-19 over a 5-month period. We obtained clinical, microbiologic and laboratory data from electronic medical records. Propensity-score-matching helped create balanced exposure groups. Demographic characteristics were compared across outcome groups (BSI/no BSI) using two-sample t-test and Chi-Square test for continuous and categorical variables respectively, while immunosuppressive therapy use was compared using McNemar’s test. Conditional logistic regression helped assess the association between immunosuppressive therapies and BSIs. 13,007 patients were originally included, with propensity-score-matching producing a sample of 6,520 patients. 3.74% and 3.97% were diagnosed with clinically significant BSIs in the original and propensity-score-matched populations respectively. COVID-19 patients with BSIs had significantly longer hospitalizations, higher intensive care unit admission and mortality rates compared to those without BSIs. On univariable analysis, combinations of corticosteroids/anakinra [odds-ratio (OR) 2.00, 95% confidence intervals (C.I.) 1.05-3.80, P value.0342] and corticosteroids/tocilizumab [OR 2.13, 95% C.I. 1.16–3.94, P value .0155] were significantly associated with BSIs. On multivariable analysis (adjusting for confounders), combination corticosteroids/tocilizumab were significantly associated with any BSI [OR 1.97, 95% C.I. 1.04–3.73, P value.0386] and with bacterial BSIs [OR 2.13, 95% C.I. 1.12–4.05, p-value 0.0217]. Combination immunosuppressive therapies were significantly associated with BSI occurrence in COVID-19 patients; their use warrants increased BSI surveillance. Further studies are needed to establish their causative role.
- 1 June 2021
- Published by Elsevier in Journal of Medical Mycology
- Vol. 31 (2) , 101125
Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient – Case report and review of literature
- 1 June 2021
- Published by Elsevier in Journal of Medical Mycology
- Vol. 31 (2) , 101125
Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient – Case report and review of literature